Table 3.

Final Model: Predictors of Receiving New Inhaled Therapies (LABA and/or ICS) Among 657 Patients with an Inpatient Exacerbation

Variable	Patients without change in therapy N = 430	Patients with change in therapy N = 227	Odds ratio to obtain new drug (95 % CI)	P-value
Age (each year older), μ (SD)	67.7 (11.3)	64.6 (10.5)	0.97 (0.96, 0.99)	<0.01
Race, n
White	n = 316	n = 159
Other race	n = 16	n = 6	0.61 (0.23, 1.64)	0.33
Unknown/not provided	n = 98	n = 62	1.19 (0.81, 1.75)	0.38
Prior COPD exacerbation, n	n = 347	n = 167	0.60 (0.40, 0.91)	0.02
No. of ipratroprium canisters, μ (sd)	3.9 (9.2)	3.0 (7.5)	0.99 (0.96, 1.01)	0.22
Congestive heart failure, n	n = 172	n = 50	0.46 (0.31,0.67)	<0.01
Depression, n	n = 116	n = 32	0.38 (0.24, 0.60)	<0.01
Missed appointments >1	n = 24	n = 7	0.53 (0.21,1.30)	0.16

The three models used to construct the final model were categorized by demographics and health behaviors, comorbid conditions, and markers of disease severity; these included age, BMI, race, smoking status within the past year, number of missed appointments, history of congestive heart failure, hypertension, acute coronary syndrome, diabetes, or depression, history of COPD exacerbation within the past year, canisters of short-acting beta-agonists (SABA) filled, and canisters of ipratroprium filled. See Appendix Table 2 (available online) for details